14 completed, 2 terminated, 1 recruiting, 1 unknown. 7 Phase 4, 6 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 5, Recruiting 1, Unknown 1 |
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow AST 120: new trials by email Literature Review of AST 120 trials Research Report on AST 120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease AST-120 (Kremezin®) - Acute Kidney Disease, Acute Kidney Injury (AKI) | Phase 4 | Recruiting | Chang Gung Memorial Hospital | 100 | 2025-09-15 | 2025-09-19 |
| AST-120 in Hemodialysis Patients With Uremic Pruritus AST-120 - Uremic Pruritus | Phase 4 | Completed | Conmed Pharmaceutical & Bio-Medical Corporation | 100 | 2020-07-02 | 2023-09-07 |
| Pharmacokinetic Study of ASP1517 With Kremezin® ASP1517, Kremezin® - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Inc | 34 | 2016-02-01 | 2016-06-21 |
| Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation Kremezin - Loss of Solute Clearance | Phase 4 | Completed | Tungs' Taichung Metroharbour Hospital | 30 | 2011-01-01 | 2014-05-09 |
| The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Kremezin - Kidney Failure, Chronic | Phase 4 | Unknown | Ewha Womans University | 30 | 2010-09-01 | 2010-07-07 |
| AST-120 Used to Treat Mild Hepatic Encephalopathy AST-120 - Mild Hepatic Encephalopathy | Phase 2 | Completed | Ocera Therapeutics | 148 | 2009-03-01 | 2014-06-18 |
| Kremezin Study Against Renal Disease Progression in Korea AST-120 - Chronic Kidney Disease | Phase 4 | Completed | Seoul National University Hospital | 578 | 2009-03-01 | 2014-03-19 |
| Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients. AST-120 - Chronic Kidney Disease, AST-120 | Phase 4 | Completed | Chang Gung Memorial Hospital | 51 | 2009-01-01 | 2013-08-06 |
| Drug-Drug Interaction Study of TRK-100STP TRK-100STP (BERASUS LA), AST-120 (Kremezin®) - Healthy | Phase 1 | Completed | Astellas Pharma Inc | 24 | 2008-06-01 | 2008-10-13 |
| Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI AST-120, Celphere CP-305 - Gastroesophageal Reflux Disease (GERD) | Phase 2 | Terminated | Ocera Therapeutics | 4 | 2007-10-01 | 2014-06-18 |
| Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy AST-120, lactulose - Hepatic Encephalopathy | Phase 2 | Completed | Ocera Therapeutics | 40 | 2007-09-01 | 2014-05-30 |
| Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome AST-120, Celphere® CP-305 - Irritable Bowel Syndrome | Phase 2 | Completed | Ocera Therapeutics | 117 | 2007-08-01 | 2014-06-18 |
| A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) Placebo, AST-120 - Chronic Kidney Disease | Phase 3 | Completed | Tanabe Pharma Corporation | 1020 | 2007-07-01 | 2026-01-08 |
| A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) Placebo, AST-120 - Chronic Kidney Disease | Phase 3 | Completed | Tanabe Pharma Corporation | 1015 | 2007-07-01 | 2026-01-08 |
| Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis AST-120 - Pouchitis | Phase 2 | Terminated | Ocera Therapeutics | 2 | 2007-03-01 | 2014-06-18 |
| Safety and Efficacy of AST-120 in the Treatment of Pouchitis AST-120 - Pouchitis | Phase 2 | Completed | Ocera Therapeutics | 19 | 2007-02-01 | 2014-06-18 |
| Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas AST-120 - Inflammatory Bowel Disease, Intestinal Fistula | Phase 3 | Completed | Ocera Therapeutics | 191 | 2006-03-01 | 2014-05-30 |
| Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease Kremezin - Kidney Failure, Chronic | Phase 4 | Completed | Institute for Health Outcomes and Process Evaluation Reseach | 450 | 2004-04-01 | 2007-10-18 |
Renal Insufficiency, Chronic (5) · Hepatic Encephalopathy (2) · Kidney Diseases (2) · Kidney Failure, Chronic (2) · Liver Diseases (2) · Pouchitis (2) · Acute Kidney Injury (1) · Brain Diseases (1) · Cognitive Dysfunction (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Fibrosis (1) · Fistula (1) · Gastroesophageal Reflux (1) · Inflammatory Bowel Diseases (1)
Ocera Therapeutics (7) · Astellas Pharma Inc (2) · Chang Gung Memorial Hospital (2) · Tanabe Pharma Corporation (2) · Conmed Pharmaceutical & Bio-Medical Corporation (1) · Ewha Womans University (1) · Institute for Health Outcomes and Process Evaluation Reseach (1) · Seoul National University Hospital (1) · Tungs' Taichung Metroharbour Hospital (1)
United States (9) · Taiwan (4) · Canada (3) · Czechia (3) · Japan (3) · Poland (3) · Argentina (2) · Belgium (2) · Brazil (2) · France (2) · Germany (2) · Mexico (2) · Puerto Rico (2) · Russia (2) · South Korea (2)
Bo Shen, MD (1) · Chia-Chao Wu, Dr. (1) · Darrell S. Pardi, MD (1) · Duk-Hee Kang, MD. PhD. (1) · I-Wen Wu, MD (1) · Jan Tack, MD (1) · Jeff Bornstein, MD (1) · Jian-Lin Lu, Dr. (1) · Kuo-Cheng Lu, Dr. (1) · Laurent Fischer, MD (1) · Lim Paik-Seong (1) · Lin-Kuo Ko, Dr. (1)
PMID 25349205, PMID 27716149, PMID 28741050, PMID 19615804, PMID 21883322, PMID 27249416, PMID 29172403, PMID 30975656